Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia - PubMed (original) (raw)
. 2010 Dec 2;116(23):4958-67.
doi: 10.1182/blood-2010-01-266999. Epub 2010 Aug 20.
Harry Erba, Peter Ouillette, Diane Roulston, Anjali Purkayastha, Judith Karp, Moshe Talpaz, Lisa Kujawski, Sajid Shakhan, Cheng Li, Kerby Shedden, Sami N Malek
Affiliations
- PMID: 20729466
- PMCID: PMC3012590
- DOI: 10.1182/blood-2010-01-266999
Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia
Brian Parkin et al. Blood. 2010.
Abstract
Genomic aberrations are of predominant importance to the biology and clinical outcome of patients with acute myelogenous leukemia (AML), and conventional karyotype-based risk classifications are routinely used in clinical decision making in AML. One of the known limitations of cytogenetic analysis is the inability to detect genomic abnormalities less than 5 Mb in size, and it is currently unclear whether overcoming this limitation with high-resolution genomic single-nucleotide polymorphism (SNP) array analysis would be clinically relevant. Furthermore, given the heterogeneity of molecular mechanisms/aberrations that underlie the conventional karyotype-based risk classifications, it is likely that further refinements in genomic risk prognostication can be achieved. In this study, we analyzed flow cytometer-sorted, AML blast-derived, and paired, buccal DNA from 114 previously untreated prospectively enrolled AML patients for acquired genomic copy number changes and loss of heterozygosity using Affymetrix SNP 6.0 arrays, and we correlated genomic lesion load and specific chromosomal abnormalities with patient survival. Using multivariate analyses, we found that having ≥ 2 genomic lesions detected through SNP 6.0 array profiling approximately doubles the risk of death when controlling for age- and karyotype-based risk. Finally, we identified an independent negative prognostic impact of p53 mutations, or p53 mutations and 17p-loss of heterozygosity combined on survival in AML.
Figures
Figure 1
Whole genome copy number heatmap display of 114 AML genomes: Copy number heatmap displays for paired DNA samples based on SNP 6.0 array profiling were generated using dChipSNP. (Left panel) Buccal DNA. (Right panel) AML blast DNA. Samples are grouped by AML subtype (primary, secondary, and treatment-related) and by chromosome number (1-22 and X). Blue indicates copy loss, red indicates copy gain. Each column represents one patient.
Figure 2
SNP 6.0 array-based lesion cutoffs and OS in AML (Kaplan-Meier plots). (A-D) All-treatment group. (E-H) Intensive-treatment group.
Figure 3
Specific SNP 6.0 array-based genomic lesions and OS in AML (Kaplan-Meier plots). (A-D) All-treatment group. (E-H) Intensive-treatment group.
Figure 4
SNP 6.0 array-based lesion cutoffs and cytogenetic risk group and OS in AML (Kaplan-Meier plots). (A-D) All-treatment group. (E-H) Intensive-treatment group.
Similar articles
- Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K. Svobodova K, et al. Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009. Epub 2016 Jan 24. Leuk Res. 2016. PMID: 26851439 - Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.
Parkin B, Ouillette P, Yildiz M, Saiya-Cork K, Shedden K, Malek SN. Parkin B, et al. Clin Cancer Res. 2015 May 1;21(9):2045-56. doi: 10.1158/1078-0432.CCR-14-0921. Epub 2015 Feb 4. Clin Cancer Res. 2015. PMID: 25652455 Free PMC article. - Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
Ronaghy A, Yang RK, Khoury JD, Kanagal-Shamanna R. Ronaghy A, et al. Curr Hematol Malig Rep. 2020 Jun;15(3):194-202. doi: 10.1007/s11899-020-00578-1. Curr Hematol Malig Rep. 2020. PMID: 32382988 Review. - Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights.
Bullinger L, Fröhling S. Bullinger L, et al. Semin Oncol. 2012 Feb;39(1):37-46. doi: 10.1053/j.seminoncol.2011.11.005. Semin Oncol. 2012. PMID: 22289490 Review.
Cited by
- Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype.
Ibáñez M, Such E, Onecha E, Gómez-Seguí I, Liquori A, Sellés J, Hervás-Marín D, Barragán E, Ayala R, LLop M, López-Pavía M, Rapado I, Neef A, Sanjuan-Pla A, Sargas C, Gonzalez-Romero E, Boluda-Navarro M, Andreu R, Senent L, Montesinos P, Martínez-López J, Angel Sanz M, Sanz G, Cervera J. Ibáñez M, et al. Sci Rep. 2020 Apr 3;10(1):5904. doi: 10.1038/s41598-020-61589-9. Sci Rep. 2020. PMID: 32246042 Free PMC article. - Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype.
Fenwarth L, Duployez N, Thomas X, Boissel N, Geffroy S, Marceau-Renaut A, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Cheok MH, Peyrouze P, Pigneux A, Vey N, Celli-Lebras K, Terré C, Preudhomme C, Dombret H. Fenwarth L, et al. Cancers (Basel). 2019 Dec 30;12(1):88. doi: 10.3390/cancers12010088. Cancers (Basel). 2019. PMID: 31905904 Free PMC article. - Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.
Walker CJ, Kohlschmidt J, Eisfeld AK, Mrózek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. Walker CJ, et al. Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. Epub 2019 Aug 2. Clin Cancer Res. 2019. PMID: 31375516 Free PMC article. - Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G. Fontana MC, et al. Leukemia. 2018 Jul;32(7):1609-1620. doi: 10.1038/s41375-018-0035-y. Epub 2018 Feb 23. Leukemia. 2018. PMID: 29472722 Free PMC article. - Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.
Parkin B, Londoño-Joshi A, Kang Q, Tewari M, Rhim AD, Malek SN. Parkin B, et al. J Clin Invest. 2017 Sep 1;127(9):3484-3495. doi: 10.1172/JCI91964. Epub 2017 Aug 21. J Clin Invest. 2017. PMID: 28825596 Free PMC article. Clinical Trial.
References
- Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–1918. - PubMed
- Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22(2):240–248. - PubMed
- Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–4336. - PubMed
- Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322–2333. - PubMed
- Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–4083. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA046592/CA/NCI NIH HHS/United States
- R01 CA136537/CA/NCI NIH HHS/United States
- 5 P30 CA46592/CA/NCI NIH HHS/United States
- 1R01 CA136537-01/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous